May 9, 2023 Experience ACELYRIN $621 million IPO The stock is listed on the Nasdaq Global Select Market
May 8, 2023 Experience Kenvue $4.37 billion IPO The carve-out of the former Johnson & Johnson consumer health business is the largest U.S. IPO since November 2021
May 3, 2023 Experience Cellular Biomedicine Group CAR-T collaboration and license agreement with Janssen We are advising Cellular Biomedicine Group on the transaction
March 7, 2023 Experience Atairos acquisition of LifeLabs Learning We are advising Atairos on the transaction
March 3, 2023 Experience European Biotech Acquisition $220 million combination with Oculis We advised European Biotech Acquisition on its de-SPAC transaction
January 19, 2023 Experience Sun Pharmaceutical acquisition of Concert Pharmaceuticals We advised Sun Pharmaceutical on the transaction
December 14, 2022 Experience Priveterra Acquisition initial business combination with AEON Biopharma We are advising Priveterra on the transaction
November 22, 2022 Experience TMS ¥2.9 billion global IPO The shares are listed on the Tokyo Stock Exchange
November 15, 2022 Experience Metalmark Capital up to $50 million investment in Morgenesis We advised Metalmark on the transaction
November 9, 2022 Experience Molded Devices acquisition of GlobalMed and Schauenburg-Truplast We advised Molded Devices on the acquisition and the related financing arrangements